Create a narrative

CorMedix Community

NasdaqGM:CRMD Community

1 Narratives written by author
0 Comments on narratives written by author
21 Fair Values set on narratives written by author

Create a narrative

AN

AnalystConsensusTarget

Consensus Narrative from 6 Analysts

DefenCath Launch Will Boost Inpatient And Dialysis Opportunities

Key Takeaways Strong revenue growth prospects from DefenCath's successful launch and expansion into new segments like inpatient facilities and partnerships. Upcoming collaborations and clinical studies aim to enhance market positioning, potentially driving future revenue through demonstrated efficacy and increased market penetration.

US$15.50

FV

24.6% undervalued

82.17%

Revenue growth p.a.

0

0

3

7 days ago